Literature DB >> 23695214

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Juha J Hulmi1, Bernardo M Oliveira, Mika Silvennoinen, Willem M H Hoogaars, Arja Pasternack, Heikki Kainulainen, Olli Ritvos.   

Abstract

The importance of adequate levels of muscle size and function and physical activity is widely recognized. Myostatin/activin blocking increases skeletal muscle mass but may decrease muscle oxidative capacity and can thus be hypothesized to affect voluntary physical activity. Soluble activin receptor IIB (sActRIIB-Fc) was produced to block myostatin/activins. Modestly dystrophic mdx mice were injected with sActRIIB-Fc or PBS with or without voluntary wheel running exercise for 7 wk. Healthy mice served as controls. Running for 7 wk attenuated the sActRIIB-Fc-induced increase in body mass by decreasing fat mass. Running also enhanced/restored the markers of muscle oxidative capacity and autophagy in mdx mice to or above the levels of healthy mice. Voluntary running activity was decreased by sActRIIB-Fc during the first 3-4 wk correlating with increased body mass. Home cage physical activity of mice, quantified from the force plate signal, was decreased by sActRIIB-Fc the whole 7-wk treatment in sedentary mice. To understand what happens during the first weeks after sActRIIB-Fc administration, when mice are less active, healthy mice were injected with sActRIIB-Fc or PBS for 2 wk. During the sActRIIB-Fc-induced rapid 2-wk muscle growth period, oxidative capacity and autophagy were reduced, which may possibly explain the decreased running activity. These results show that increased muscle size and decreased markers of oxidative capacity and autophagy during the first weeks of myostatin/activin blocking are associated with decreased voluntary activity levels. Voluntary exercise in dystrophic mice enhances the markers of oxidative capacity and autophagy to or above the levels of healthy mice.

Entities:  

Keywords:  activin receptor IIB; exercise; hypertrophy; myostatin; skeletal muscle

Mesh:

Substances:

Year:  2013        PMID: 23695214     DOI: 10.1152/ajpendo.00065.2013

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  20 in total

Review 1.  Proteotoxicity and cardiac dysfunction.

Authors:  Patrick M McLendon; Jeffrey Robbins
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

2.  Vitamin C and E supplementation alters protein signalling after a strength training session, but not muscle growth during 10 weeks of training.

Authors:  G Paulsen; H Hamarsland; K T Cumming; R E Johansen; J J Hulmi; E Børsheim; H Wiig; I Garthe; T Raastad
Journal:  J Physiol       Date:  2014-11-10       Impact factor: 5.182

3.  Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.

Authors:  Caroline Barbé; Stéphanie Kalista; Audrey Loumaye; Olli Ritvos; Pascale Lause; Benjamin Ferracin; Jean-Paul Thissen
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-28       Impact factor: 4.310

Review 4.  Heat shock response and autophagy--cooperation and control.

Authors:  Karol Dokladny; Orrin B Myers; Pope L Moseley
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

5.  Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.

Authors:  Míriam Toledo; Fabio Penna; Sílvia Busquets; Francisco J López-Soriano; Josep M Argilés
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

6.  Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function.

Authors:  Alexander Michael Tabony; Tadashi Yoshida; Sergiy Sukhanov; Patrice Delafontaine
Journal:  Skelet Muscle       Date:  2014-10-30       Impact factor: 4.912

7.  Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients.

Authors:  Janek Hyzewicz; Urs T Ruegg; Shin'ichi Takeda
Journal:  J Neuromuscul Dis       Date:  2015-11-22

8.  Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Authors:  Tero Puolakkainen; Hongqian Ma; Heikki Kainulainen; Arja Pasternack; Timo Rantalainen; Olli Ritvos; Kristiina Heikinheimo; Juha J Hulmi; Riku Kiviranta
Journal:  BMC Musculoskelet Disord       Date:  2017-01-19       Impact factor: 2.362

Review 9.  Skeletal muscle homeostasis in duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy.

Authors:  Clara De Palma; Cristiana Perrotta; Paolo Pellegrino; Emilio Clementi; Davide Cervia
Journal:  Front Aging Neurosci       Date:  2014-07-24       Impact factor: 5.750

10.  Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.

Authors:  T A Nissinen; J Degerman; M Räsänen; A R Poikonen; S Koskinen; E Mervaala; A Pasternack; O Ritvos; R Kivelä; J J Hulmi
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.